Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.03 USD | -0.36% | -7.51% | +179.21% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 6.29M | Capitalization | 332M |
---|---|---|---|---|---|
Net income 2024 * | -71M | Net income 2025 * | -74M | EV / Sales 2024 * | - |
Net cash position 2024 * | 217M | Net cash position 2025 * | - | EV / Sales 2025 * | 52.9 x |
P/E ratio 2024 * |
-4.43
x | P/E ratio 2025 * |
-5.56
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.36% |
Latest transcript on Jasper Therapeutics, Inc.
1 day | -0.36% | ||
1 week | -7.51% | ||
Current month | -24.97% | ||
1 month | -24.63% | ||
3 months | +103.98% | ||
6 months | +192.49% | ||
Current year | +179.21% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 23-09-21 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Thomas Wiggans
CHM | Chairman | 72 | Oct. 31 |
Kurt von Emster
BRD | Director/Board Member | 56 | 21-09-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 22.03 | -0.36% | 44,701 |
24-04-23 | 22.11 | -1.82% | 77,665 |
24-04-22 | 22.52 | +4.31% | 86,432 |
24-04-19 | 21.59 | -6.98% | 64,582 |
24-04-18 | 23.21 | -2.56% | 120,088 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+179.21% | 332M | |
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- JSPR Stock